GlassScriptPhysician profile
Jose Pablo Febrillet
NPI 1659502235
$5,277.12
in general payments reported to CMS, 2019-2025
28 companies · $661 in 2025
The $661 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,752 · 2022: $1,288 · 2023: $1,106 · 2024: $470 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $912.08 | 2021-2024 | Trelegy Ellipta, Shingrix, Nucala |
| Astrazeneca Pharmaceuticals LP | $855.40 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $755.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.99 | 2021-2023 | Jardiance |
| Amgen INC. | $454.97 | 2022-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $268.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.42 | 2021-2023 | |
| Mylan Specialty L.P. | $178.62 | 2021-2023 | Yupelri |
| Exact Sciences Corporation | $162.72 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $151.36 | 2023-2025 | Freestyle Libre |
| Lilly USA, LLC | $147.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Incyte Corporation | $102.80 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $94.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $60.37 | 2025 | Rexulti |
| Ardelyx, INC. | $48.81 | 2023 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.50 | 2021 | |
| Intuity Medical INC | $39.31 | 2022 | |
| Abiomed | $38.65 | 2023 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.25 | 2022 | |
| Pfizer INC. | $31.08 | 2022 | |
| Scpharmaceuticals INC. | $26.24 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.05 | 2022 | |
| Seqirus USA INC | $19.98 | 2022 | |
| Qorumpartners | $19.71 | 2022 | |
| Hologic Sales and Service, LLC | $18.58 | 2025 | Aptima |
| Dexcom, INC. | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Febrillet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.